1092939-15-5 Usage
Description
(betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile (2Z)-2-butenedioate, also known as B 708, is a pyrazole derivative featuring a cyclopentyl group and a pyrrolopyrimidine moiety. This unique chemical structure endows it with potential biological activity, making it a promising candidate for pharmaceutical and medicinal chemistry applications.
Uses
Used in Pharmaceutical Development:
(betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile (2Z)-2-butenedioate is used as a key intermediate in the synthesis of novel pharmaceutical compounds. Its unique structure allows for the development of drugs with specific targeting and therapeutic properties.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile (2Z)-2-butenedioate serves as a valuable compound for studying the structure-activity relationships of potential drug candidates. Its incorporation into various chemical libraries aids in the discovery of new therapeutic agents.
Further research is necessary to fully explore the properties and potential applications of (betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile (2Z)-2-butenedioate, as its current uses are based on its unique structure and potential biological activity.
Check Digit Verification of cas no
The CAS Registry Mumber 1092939-15-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,2,9,3 and 9 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1092939-15:
(9*1)+(8*0)+(7*9)+(6*2)+(5*9)+(4*3)+(3*9)+(2*1)+(1*5)=175
175 % 10 = 5
So 1092939-15-5 is a valid CAS Registry Number.
1092939-15-5Relevant articles and documents
JAK PI3K/mTOR combination therapy
-
, (2016/06/28)
Provided herein is a combination therapy comprising a JAK kinase inhibitor and a dual PI3K/mTOR inhibitor, as well as methods of treating various cancers through the use of such a combination therapy.
SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE
-
Page/Page column 6, (2009/01/24)
The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
